This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Passage Bio (AAV-delivered gene therapies for rare monogenic CNS diseases) closed a $110mm Series B financing round led by life sciences investment firm Access Biotechnology (added a board member), which was joined by returning backers OrbiMed, Frazier Healthcare Partners, Versant Ventures, Lily Asia Ventures, New Leaf Venture Partners, and Vivo Capital, along with new investors Boxer Capital of Tavistock Group, Highline Capital Management, Logos Capital, and Sphera Funds Management. Launched earlier this year with a $115.5mm Series A round, Passage will use the proceeds to support further development of its five pipeline programs in-licensed from UPenn. Clinical trials for its lead candidates in GM1 gangliosidosis and frontotemporal dementia are expected in 1H 2020.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?